F/M Investments’s NovoCure NVCR Stock Holding History

F/M Investments’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-19,173	Closed	-$248K	–	449
2025 Q3	$248K	Sell	19,173 -15,387	-45%	-$206K	0.01%	388
2025 Q2	$615K	Buy	34,560 +461	+1%	+$8.03K	0.02%	316
2025 Q1	$608K	Buy	34,099 +1,999	+6%	+$45.4K	0.02%	317
2024 Q4	$957K	Buy	+32,100	New	+$679K	0.04%	289

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

F/M Investments's NVCR Position: Q4 2025 in Review

F/M Investments sold out of NovoCure (NVCR) in Q4 2025, closing a stake of 19,173 shares — an estimated $248K sold.

F/M Investments first reported a position in NVCR in Q4 2024 and held it in 4 quarters. The position peaked at $957K in Q4 2024. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2025.

F/M Investments reported no remaining NovoCure position as of Q4 2025 after selling out during the quarter.
F/M Investments sold 19,173 NovoCure shares in Q4 2025, an estimated $248K.
F/M Investments first reported a position in NovoCure in Q4 2024 and held it in 4 quarters.
F/M Investments's NovoCure position peaked at $957K in Q4 2024.
238 funds tracked by Wall St. Rank held NovoCure as of Q4 2025.

Based on F/M Investments's 13F filing for Q4 2025, filed 3 Feb 2026.